Impact of intravesical Bacillus Calmette-Guerin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.

ABSTRACT:

Introduction

Intravesical therapy (IVT), including Bacillus Calmette-Guérin (BCG), is the standard of care for high grade (HG) non-muscle invasive bladder cancer (NMIBC). Despite the use of IVT, many patients recur after treatment. The bladder microbiome and its role in disease processes has recently risen to prominence. We aim to characterize changes that occur in the bladder microbiome over the course of intravesical therapy and assess whether these changes correlate with outcomes in patients with NMIBC.

Methods

Patients with NMIBC undergoing induction BCG or intravesical therapy were prospectively enrolled from January 2019 to March 2020. Patients with clinical T2 or greater pathology or active urinary tract infection at enrollment were excluded. Twenty-nine patients had

SUBMITTER: James C 

PROVIDER: S-EPMC10114608 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature